Bold claim: a new test can tell apart vaccine-induced false positives from real HIV infection, potentially speeding up HIV vaccine development. While major strides continue in HIV vaccine research, there is still no approved HIV vaccine, notes Penn State Professor Dipanjan Pan. Research is active, with multiple preventive and therapeutic strategies under investigation, but some vaccine candidates may trigger false-positive HIV tests, complicating diagnosis and patient management.
To address this challenge, Pan and his team devised an approach that distinguishes active HIV infection from vaccine-induced signals that could lead to false positives. This advancement could streamline vaccine testing and development, Pan explains. The researchers collaborated with the HIV Vaccine Trials Network, sponsored by the NIH Vaccine Research Center, to examine 104 human blood samples using the new device. The test employs a blend of analyses and delivers results in about five minutes. It correctly identified active HIV-1 infection 95% of the time and accurately flagged samples without active infection but with vaccine-related molecules that might cause false positives 98% of the time. In short, the method meets or surpasses the performance of existing approaches, according to Pan.
The team published their findings in Science Advances and have also filed a patent related to the technology. For full details, read the press coverage or the original Science Advances article at the provided links.
